OpenDNA
OpenDNA is a privately held biotech that offers AI-powered genomic risk assessment tools (CardioRisk+, CancerRisk+, TotalRisk+, PolyRisk+) to physicians for predicting complex diseases, combining polygenic risk scores with clinical data and integrating results into EMR workflows.
- Company typePrivate
- Founded-
- HeadquartersHaifa, Israel
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What OpenDNA does
OpenDNA is a privately held biotechnology company that offers AI-powered genomic risk assessment tools to clinicians for the prediction of complex diseases. The company operates dual legal entities, OpenDNA LLC in the United States (headquartered in Clarksburg, Maryland) and OpenDNA Ltd. in Israel (Haifa), and maintains a small team of 1-10 employees. Its core product is a patented AI platform that combines validated polygenic risk scores (PRS) with clinical data (family history, lifestyle, biomarkers) to generate personalized risk profiles across cardiovascular disease, cancer, and other chronic conditions. The platform is validated on a database of more than 500,000 individuals and claims 85% accuracy in predicting heart attacks; clinical validation includes the 10-year MI-GENES trial, a 287-patient Mayo Clinic study, and a 150-patient multi-clinic trial.
The product portfolio comprises four physician-ordered tests: CardioRisk+ for cardiometabolic disease, CancerRisk+ for polygenic cancer risk, TotalRisk+ (the only AI tool combining polygenic risk scoring with monogenic testing including a 29-gene panel) for comprehensive cancer risk, and PolyRisk+ covering 30+ conditions across eight disease categories. The platform integrates with electronic medical records (EMR) for single sign-on, automated ordering, and interactive 'what-if' dashboards, with sample processing handled by affiliated laboratory GeneByGene. OpenDNA also holds an exclusive license to Cleveland Clinic's polygenic technology for personalized diabetes treatment.
Revenue is generated through one-time genetic testing services sold to healthcare providers, with tests ordered by physicians and delivered through a secure provider portal. The go-to-market is sales-led via direct enterprise relationships with concierge medicine practices, primary care groups, and specialists, with McKesson serving as the US distribution partner and Mayo Clinic as a research collaborator. Customers disclosed include Harper Health, PartnerMD, Encore Concierge Medicine, Blossom Family Medicine, Salveo Direct Care, Adventist HealthCare Cardiac Associates, and Dr. Sean Cahill's practice, alongside a 2025 research collaboration with Israel's Psifas national biobank initiative. No public funding rounds or revenue figures are disclosed.
OpenDNA firmographics
Firmographics- Name
- OpenDNA
- Legal name
- OpenDNA Ltd.
- Website
- https://open-dna.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OpenDNA is a privately held biotech that offers AI-powered genomic risk assessment tools (CardioRisk+, CancerRisk+, TotalRisk+, PolyRisk+) to physicians for predicting complex diseases, combining polygenic risk scores with clinical data and integrating results into EMR workflows.
- Ownership category
- akta.pro rank
OpenDNA industry classification
Industry- Product category
- Clinical Genomics & Genetic Risk Assessment Software
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industries
- Population Genomics & Preventive Precision Health Programs (HLAAANAL), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where OpenDNA is headquartered
LocationHeadquarters
- HQ city
- Haifa
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
OpenDNA business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Genetic Testing Services: OpenDNA generates revenue through AI-powered genetic testing services sold to healthcare providers. Tests are ordered by physicians and delivered through a secure provider portal with results in an accessible, physician-ready format.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
OpenDNA product offering
Product offeringCore offering
OpenDNA sells AI-powered genetic testing services to healthcare providers. Physicians order genetic tests through a secure provider portal; OpenDNA's platform combines polygenic risk scores with clinical data to generate personalized risk profiles for cardiovascular disease, cancer, autoimmune, neurological, mental health, respiratory, women's health, and eye conditions. Results are delivered in a physician-ready format through the platform with interactive dashboards for shared decision-making.
Product overview
OpenDNA offers a unified AI-powered genomic platform with four integrated genetic risk assessment products: CardioRisk+ for cardiovascular and cardiometabolic disease prediction, CancerRisk+ for cancer risk assessment using polygenic risk scores, TotalRisk+ as the only polygenic-monogenic combined cancer risk tool, and PolyRisk+ as the broadest panel covering 30+ conditions across eight disease categories. The platform integrates genomics with clinical data, provides interactive dashboards for 'what-if' risk modeling, and delivers results via secure EMR-integrated portals. All tests are physician-ordered and use buccal swab sample collection.
Differentiator
Problem solved
Functional benefit
Brands
- CardioRisk+: AI-powered cardiovascular risk assessment tool that provides earlier, more accurate risk detection for heart attack, diabetes, hypertension, and other cardiometabolic conditions.
- CancerRisk+
- TotalRisk+
- PolyRisk+
Products and services
- CardioRisk+ AI-powered cardiovascular risk assessment tool that predicts heart attack risk, diabetes, hypertension, high cholesterol, obesity, atrial fibrillation, chronic kidney disease, MASLD, and venous thromboembolism by combining polygenic risk scores with clinical data; for healthcare providers and clinicians ordering preventive genetic tests.
- CancerRisk+ AI-powered cancer risk assessment tool using polygenic risk scoring to assess breast, colon, prostate, lung cancer, melanoma, and ovarian cancer risk with actionable recommendations for personalized screening and treatment; for healthcare providers offering preventive oncology testing.
- TotalRisk+ AI-powered genetic test combining polygenic risk scoring and monogenic testing (29-gene monogenic panel including BRCA and Lynch Syndrome) for comprehensive cancer genetic risk assessment; for clinicians offering complete cancer genetic screening.
- PolyRisk+ Broadest AI-powered polygenic risk panel assessing genetic susceptibility across eight disease areas (CardioRisk+, CancerRisk+, AutoimmuneRisk+, NeuroRisk+, MentalHealthRisk+, RespiratoryRisk+, WomenHealthRisk+, and EyeRisk+) covering over 30 complex conditions; for clinicians seeking a single broad genetic risk assessment.
Quantifiable outcome
- 80% sensitivity for CHD events when combining AI model with CAC score
- +9 more outcomes
Companies that use OpenDNA
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles3 records
OpenDNA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature6 records
OpenDNA partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core.
- Salveo Direct CarecoreFirst clinic in San Antonio to offer OpenDNA's advanced genetic testing, providing patients with personalized insights into their genetic health risks.
- Dr. Sean CahillcorePartnership to bring advanced genetic testing to Chicago-area patients, offering comprehensive PRS technology for disease screening, hereditary cancer risk, and chronic condition predisposition.
- Psifas (Israel's National Initiative for Personalized Medicine)coreMajor research collaboration to develop 32 polygenic risk score models for conditions including cardiovascular disease, breast cancer, prostate cancer, and colorectal cancer using Psifas's extensive clinical and genetic biobank.
- Blossom Family MedicinecorePartnership to bring precision genetic testing into primary care setting, integrating CardioRisk+, CancerRisk+, and TotalRisk+ into routine visits.
- Encore Concierge MedicinecoreStrategic partnership to deliver advanced AI-driven genetic risk tests (CardioRisk+, CancerRisk+, TotalRisk+) for personalized preventive care.
- Harper HealthcoreClinical partnership to provide AI-based genetic risk testing to patients. Harper Health integrates OpenDNA's CardioRisk+, CancerRisk+, and TotalRisk+ tests into their personalized concierge care model.
- Mayo CliniccoreCollaborative research partnership for AI-powered heart disease risk prediction using polygenic risk scores. Presented at ACC 2025 demonstrating AI model with AUC of 0.74 when combined with CAC score.
- PartnerMDcoreCommercial partnership to deliver AI-based genetic risk testing for cardiometabolic diseases. PartnerMD offers CardioRisk+ test analyzing more than 6 million SNPs alongside clinical biomarkers.
- Mayo CliniccoreKnow-how and research agreement for AI cardiovascular disease prediction as part of pilot clinical study led by Dr. Regis I. Fernandes at Mayo Clinic Arizona.
- McKessoncoreMcKesson is OpenDNA's US distribution partner, enabling broader market reach through their healthcare distribution network.
- Cleveland CliniccoreExclusive license agreement to commercialize Cleveland Clinic's polygenic technology for personalized diabetes treatment, identifying patients who could benefit most from intensive type 2 diabetes therapy.
- GeneByGenecoreDNA samples are securely stored and processed by GeneByGene, OpenDNA's affiliated genetic testing laboratory. Handles sample processing and storage according to industry-standard privacy and security practices.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
OpenDNA competitors and assessment
Company assessmentDirect peers
- Helix: Helix operates a genomic testing platform that enables population genomics and clinical genetic testing applications. It parallels OpenDNA's platform approach of combining genetic data with clinical insights for disease risk prediction.
- Color Health: Color Health provides clinical-grade genetic testing for cancer risk, hereditary conditions, and pharmacogenomics through healthcare partnerships. It directly competes with OpenDNA's TotalRisk+ and CancerRisk+ offerings in physician-ordered genetic testing.
- 23andMe: 23andMe offers direct-to-consumer and clinical genetic testing including polygenic risk scores for conditions like cancer and heart disease. As a direct competitor in the PRS-based genetic risk assessment market, it shares OpenDNA's target of delivering genetic insights for disease prevention.
Emerging players
- Genetic Technologies (GTG): Genetic Technologies develops polygenic risk score-based tests for breast cancer and other complex diseases. As an emerging PRS company with similar technological foundations, it represents a direct emerging competitor to OpenDNA's CancerRisk+ and PolyRisk+ products.
- Genomic Prediction: Genomic Prediction focuses specifically on polygenic risk scoring across multiple disease areas. As an emerging PRS-focused company, it shares OpenDNA's specialized focus on AI-driven genetic risk assessment, though with different therapeutic priorities.
- Thorne: Thorne offers at-home health tests including genetic and biomarker assessments through a direct-to-consumer model. While primarily consumer-focused, its expansion into clinical-grade genetic testing creates overlap with OpenDNA's concierge medicine channel.
Broad incumbents
- Myriad Genetics: Myriad Genetics is an established leader in genetic testing, particularly for hereditary cancer (BRCA, Lynch Syndrome). Its broader portfolio and existing payer relationships make it a broad incumbent that competes with OpenDNA's monogenic and polygenic cancer risk offerings.
- Natera: Natera provides genetic testing in reproductive health, oncology, and organ transplantation. While operating in adjacent areas, its scale and established clinician relationships position it as a broad incumbent that could expand into OpenDNA's cardiovascular and cancer risk territories.
- Sema4: Sema4 (now part of GeneDx) offers clinical genomic testing and population health genomics. Its integration of AI-driven genomic analysis with clinical decision support parallels OpenDNA's platform approach, making it a comparable broad incumbent.
- Invitae: Invitae (now part of Labcorp) offers a comprehensive menu of genetic tests including hereditary cancer and cardiovascular panels. Its established infrastructure and broad test menu position it as a broad incumbent competitor to OpenDNA's specialized PRS-focused offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
OpenDNA social profiles
Digital presenceOpenDNA compliance and trust
Trust signalCompliance5 records
OpenDNA financial estimates
Financial estimateRevenue estimate
Valuation estimate
OpenDNA leadership team
Management profileNumber of profiles
Profiles10 records
OpenDNA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OpenDNA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OpenDNA
What does OpenDNA do?
OpenDNA sells AI-powered genetic testing services to healthcare providers. Physicians order genetic tests through a secure provider portal; OpenDNA's platform combines polygenic risk scores with clinical data to generate personalized risk profiles for cardiovascular disease, cancer, autoimmune, neurological, mental health, respiratory, women's health, and eye conditions. Results are delivered in a physician-ready format through the platform with interactive dashboards for shared decision-making.
Is OpenDNA a public or private company?
OpenDNA is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was OpenDNA founded?
OpenDNA was founded in -1. It employs 1 to 10 people.
Where is OpenDNA based?
OpenDNA is headquartered in Haifa, Israel, in the Middle East region.
How does OpenDNA make money?
One revenue line is on record: genetic Testing Services.
Who are OpenDNA's main competitors?
Direct peers on record are Helix, Color Health and 23andMe. Emerging players are Genetic Technologies (GTG), Genomic Prediction and Thorne. Broad incumbents are Myriad Genetics, Natera, Sema4 and Invitae.
Does OpenDNA have an API?
No public API is recorded for OpenDNA.
What industry is OpenDNA in?
OpenDNA's product category is Clinical Genomics & Genetic Risk Assessment Software. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAANAL, Population Genomics & Preventive Precision Health Programs. Its NAICS code is 621511 and its SIC code is 8071.